Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00420485
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇨🇦MD Anderson Cancer Center - Orlando, Toronto, Ontario, Canada
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00420615
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT00419159
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Phase 1
Terminated
- Conditions
- Hormone Refractory Prostate Cancer Disease
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT00419536
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2010-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT00418756
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT00418626
Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00418769
Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
Phase 1
Completed
- Conditions
- Refractory Desmoplastic Small Round Cell Tumors
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00417807
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
🇮🇹Novartis Investigative Stie, Vatania, Italy
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
Phase 2
Completed
- Conditions
- High Blood PressureMetabolic SyndromeInsulin ResistanceEndothelial Dysfunction
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00417170
- Locations
- 🇺🇸
Novartis Investigative Site, Santa Monica, California, United States
Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00416442
- Locations
- 🇬🇧
Novartis Investigative Site, Horsham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath